Adapting the Picaga Platform for Sc18F/177Lu/68Ga Labeled FAP-Targeted Radiopharmaceuticals

Abstract Fibroblast activation protein (FAP)-targeted radiopharmaceuticals have emerged as promising pan-cancer imaging and therapy agents; however, currently available platforms do not support labeling with 18F, 68Ga, and 177Lu using a single molecular precursor. Here, we describe the development of a FAP-targeted, theranostic platform based on the picaga (mpatcn-derived) chelator, capable of coordinating 18F, 68Ga, and 177Lu, followed by targeted, in vivo delivery of the radioactive payload. We synthesized three picaga-FAPI conjugates incorporating alkyl, polyethylene-glycol and poly-glycine linker architectures and evaluated their radiolabeling efficiency, FAP binding affinity, radiochemical complex stability, and in vivo performance. In competitive binding assays, picaga-FAPI and picaga-PEG3-FAPI exhibited IC50 values of 23.5 and 36.3 nM, whereas picaga-(Gly)3-FAPI exhibited diminished binding affinity, preventing determination of a corresponding IC50 value. All conjugates were successfully radiolabeled with 18F, 68Ga, and 177Lu, although radiochemical performance and molar activity varied with linker architecture, ranging from 3.7−0.37 MBq/nmol. In a FAP-expressing HT1080 xenograft model, the picaga-FAPI conjugate consistently demonstrated the highest tumor uptake across all three radionuclides, with 6.91 ± 2.13, 7.23 ± 2.10, and 5.73 ± 2.96 % ID/g for 18F, 68Ga, and 177Lu respectively. Urine metabolite analysis confirmed that the 68Ga and 177Lu complexes remained >99% and 94% intact, respectively, whereas the Sc18F complex is excreted 41% intact. Radiolabeled picaga-FAPI exhibited both the highest molar activity and the highest tumor uptake, and blocking studies verified FAP-mediated accumulation. These results establish picaga-FAPI’s suitability as a single-precursor platform for the implementation of 18F, 68Ga, and 177Lu FAP-targeted radiopharmaceuticals.

Authors

Institutions

Publication Details

Journal
Molecular Pharmaceutics
Published
2026-11-13
DOI
https://doi.org/10.1021/acs.molpharmaceut.6c00951
Primary Topic
Radiopharmaceutical Chemistry and Applications
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Adapting the Picaga Platform for Sc18F/177Lu/68Ga Labeled FAP-Targeted Radiopharmaceuticals

M. Andrey Joaqui‐Joaqui, Molly C. DeLuca, Todd E. Barnhart, Eszter Boros et al.
4 links
Molecular Pharmaceutics
Radiopharmaceutical Chemistry and Applications
article

Adapting the Picaga Platform for Sc18F/177Lu/68Ga Labeled FAP-Targeted Radiopharmaceuticals

M. Andrey Joaqui‐Joaqui, Molly C. DeLuca, Todd E. Barnhart, Eszter Boros, Dariusz Śmiłowicz, Jonathan W. Engle, Owen M. Glaser
article en

Abstract

Abstract Fibroblast activation protein (FAP)-targeted radiopharmaceuticals have emerged as promising pan-cancer imaging and therapy agents; however, currently available platforms do not support labeling with 18F, 68Ga, and 177Lu using a single molecular precursor. Here, we describe the development of a FAP-targeted, theranostic platform based on the picaga (mpatcn-derived) chelator, capable of coordinating 18F, 68Ga, and 177Lu, followed by targeted, in vivo delivery of the radioactive payload. We synthesized three picaga-FAPI conjugates incorporating alkyl, polyethylene-glycol and poly-glycine linker architectures and evaluated their radiolabeling efficiency, FAP binding affinity, radiochemical complex stability, and in vivo performance. In competitive binding assays, picaga-FAPI and picaga-PEG3-FAPI exhibited IC50 values of 23.5 and 36.3 nM, whereas picaga-(Gly)3-FAPI exhibited diminished binding affinity, preventing determination of a corresponding IC50 value. All conjugates were successfully radiolabeled with 18F, 68Ga, and 177Lu, although radiochemical performance and molar activity varied with linker architecture, ranging from 3.7−0.37 MBq/nmol. In a FAP-expressing HT1080 xenograft model, the picaga-FAPI conjugate consistently demonstrated the highest tumor uptake across all three radionuclides, with 6.91 ± 2.13, 7.23 ± 2.10, and 5.73 ± 2.96 % ID/g for 18F, 68Ga, and 177Lu respectively. Urine metabolite analysis confirmed that the 68Ga and 177Lu complexes remained >99% and 94% intact, respectively, whereas the Sc18F complex is excreted 41% intact. Radiolabeled picaga-FAPI exhibited both the highest molar activity and the highest tumor uptake, and blocking studies verified FAP-mediated accumulation. These results establish picaga-FAPI’s suitability as a single-precursor platform for the implementation of 18F, 68Ga, and 177Lu FAP-targeted radiopharmaceuticals.

Molecular Pharmaceutics
University of Wisconsin–Madison (US)
National Science Foundation, University of Wisconsin-Madison, National Institutes of Health, National Institute of Biomedical Imaging and Bioengineering, Division of Chemistry
Good health and well-being
Radiopharmaceutical Chemistry and Applications
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon